Did you know that in the last quarter of 2023, Regeneron Pharma secured leadership with an impressive 227 sequence patents?

As ST.25 transitions to ST.26 standards, Sagacious IP presents exclusive insights with our quarterly newsletter. – ‘Gene Chronicle’.

From successful Mega listing projects to our experiences in 2023, this newsletter is your compass through the evolving IP landscape.

Subscribe now for a quarterly digest designed for Sequence Listing enthusiasts like you!